Effect and safety of tirofiban in the treatment of acute coronary syndromes
10.3760/cma.j.issn.1008-6706.2014.17.008
- VernacularTitle:替罗非班治疗急性冠脉综合征的临床效果和安全性评价
- Author:
Suxia MA
- Publication Type:Journal Article
- Keywords:
Tirofiban;
Coronary artery disease;
Treatment Outcome
- From:
Chinese Journal of Primary Medicine and Pharmacy
2014;(17):2581-2582
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical efficacy and safety of tirofiban in the treatment of acute coronary syndrom.Methods 80 cases with acute coronary syndrome , were randomly divided into the observation group and control group ,two groups were given aspirin ,grey,low molecular weight heparin treatment ,the observation group was given based on the class for tirofiban intravenous injection , the control group was given a placebo , the clinical effect were compared between two groups .Results In the observation group ,30 d end point event rate of 15.00%,significantly lower than that of the control group 30.00%(χ2 =4.56,P<0.05);The observation group was administered 3 d after the electrocardiogram showed the degree of ST-T segment depression in lead and ischemia were (0.30 ±0.43)mm,(2.1 ±2.5),was significantly better than that of the control group (0.67 ±0.73) mm,(3.4 ± 2.5)(t =5.12,3.56,all P <0.05).Conclusion Aspirin,clopidogrel,heparin combined voith tirofiban can effectively improve the clinical symptoms of patients with myocardial ischemia , and can reduce the incidence of adverse events,which is worthy of clinical application .
